Note: Ingredients listed on restricted chemical lists
EC/CAS
215-647-6/1336-21-6
Name of the chemical
ammonium hydroxide
Concentration
≥1
EC/CAS
238-878-4/14808-60-7
Name of the chemical
Silica, crystalline
Concentration
≥0.001
General Information
Version
1.0
Revision date
2023-03-04
Product name
HG silver polish
1.2.2. Uses advised against
All other uses not recommended above
Manufacturer Name
HG International B.V
Emergency telephone
+31 (0)36 54 94 777, 0344 892 0111, +44 20 7188 7188
Icons in SDS
Company Information
company name
HG International B.V
e-mail address of the competent person responsible for the Safety Data Sheet
safety@hg.eu
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H315, H319
Hazard statements
Code
Statements
H315
Causes skin irritation
Section 2
SECTION 2: Hazards identification
Adverse physicochemical, human health and environmental effects
Causes skin irritation. Causes serious eye irritation.
2.2 Label elements
Labelling
Hazard pictograms
GHS07
Signal word
Warning
Hazard statements
H315 - Causes skin irritation. H319 - Causes serious eye irritation.
Precautionary statements
P101 - If medical advice is needed, have product container or label at hand. P102 - Keep out of reach of children. P264 - Wash hands thoroughly after handling. P302+P352 - IF ON SKIN: Wash with plenty of soap and water. P305+P351+P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Child-resistant fastening : Not applicable Tactile warning : Not applicable
2.3 Other hazards
This substance/mixture does not meet the PBT criteria of REACH regulation, annex XIII This substance/mixture does not meet the vPvB criteria of REACH regulation, annex XIII Contains no PBT/vPvB substances ≥ 0.1% assessed in accordance with REACH Annex XIII The mixture does not contain substance(s) included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or substances identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at a concentration equal to or greater than 0,1 %
